Efficacy of pioglitazone in improving cognitive function among dementia patients- a prospective, double blind randomized controlled trial

Background Cognitive impairment can arise from multiple neurodegenerative, vascular, metabolic, and other causes. Insulin resistance and impaired cerebral energy metabolism have been implicated in cognitive dysfunction, providing a rationale for evaluating pioglitazone as a potentially transdiagnostic metabolic intervention. This trial did not require biomarker-confirmed Alzheimer’s disease (AD); therefore, it was designed to evaluate treatment effects in adults with clinically diagnosed dementia and cognitive impairment rather than to test an AD-specific intervention. Methods In this single-centre, double-blind trial, 113 adults aged 18–64 years with clinically diagnosed dementia and cognitive impairment (Montreal Cognitive Assessment [MoCA] score < 26) were randomized to pioglitazone 15 mg once daily plus background donepezil therapy or placebo plus background donepezil therapy. Dementia was diagnosed clinically by the study neurologist using Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Pioglitazone/placebo was administered for the first 6 months, followed by a 6-month post-treatment observation period. Primary outcomes were longitudinal changes in MoCA score, P300 event-related potential (ERP) latency, P300 amplitude, and plasma Aβ42/Aβ40 ratio, analysed using mixed-model repeated-measures analysis. Safety and quality of life were secondary outcomes. Results Mixed-model repeated-measures analysis showed no statistically significant between-group differences in MoCA score ( P = 0.07), P300 latency ( P = 0.300), P300 amplitude ( P = 0.71), or plasma Aβ42/Aβ40 ratio ( P = 1.00). A total of 32 adverse drug reactions were reported; 17 (34.0%) participants in the intervention arm and 15 (30.6%) in the control arm reported at least one adverse drug reaction, with no statistically significant overall between-group difference ( P = 0.82). Conclusion In adults with clinically diagnosed dementia and cognitive impairment of unconfirmed etiology, adjunctive pioglitazone did not produce a statistically significant improvement in cognitive performance over the 12-month study period. It also did not produce detectable between-group changes in the electrophysiological or exploratory plasma amyloid measures. Because AD pathology was not established with validated central or appropriately validated blood-based biomarkers, the findings should not be interpreted as evidence for or against a disease-modifying effect of pioglitazone in AD specifically. Clinical trial number CTRI2024/09/074281. Registered on 24/09/2024

Authors

Institutions

Publication Details

Journal
Aging Clinical and Experimental Research
Published
2026-11-19
DOI
https://doi.org/10.1007/s40520-026-03556-4
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy of pioglitazone in improving cognitive function among dementia patients- a prospective, double blind randomized controlled trial

Muhasaparur Ganesan Rajanandh, Ian Osoro, Robert S. Wilson
Aging Clinical and Experimental Research
Dementia and Cognitive Impairment Research
article

Efficacy of pioglitazone in improving cognitive function among dementia patients- a prospective, double blind randomized controlled trial

Muhasaparur Ganesan Rajanandh, Ian Osoro, Robert S. Wilson
article en

Abstract

Background Cognitive impairment can arise from multiple neurodegenerative, vascular, metabolic, and other causes. Insulin resistance and impaired cerebral energy metabolism have been implicated in cognitive dysfunction, providing a rationale for evaluating pioglitazone as a potentially transdiagnostic metabolic intervention. This trial did not require biomarker-confirmed Alzheimer’s disease (AD); therefore, it was designed to evaluate treatment effects in adults with clinically diagnosed dementia and cognitive impairment rather than to test an AD-specific intervention. Methods In this single-centre, double-blind trial, 113 adults aged 18–64 years with clinically diagnosed dementia and cognitive impairment (Montreal Cognitive Assessment [MoCA] score < 26) were randomized to pioglitazone 15 mg once daily plus background donepezil therapy or placebo plus background donepezil therapy. Dementia was diagnosed clinically by the study neurologist using Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Pioglitazone/placebo was administered for the first 6 months, followed by a 6-month post-treatment observation period. Primary outcomes were longitudinal changes in MoCA score, P300 event-related potential (ERP) latency, P300 amplitude, and plasma Aβ42/Aβ40 ratio, analysed using mixed-model repeated-measures analysis. Safety and quality of life were secondary outcomes. Results Mixed-model repeated-measures analysis showed no statistically significant between-group differences in MoCA score ( P = 0.07), P300 latency ( P = 0.300), P300 amplitude ( P = 0.71), or plasma Aβ42/Aβ40 ratio ( P = 1.00). A total of 32 adverse drug reactions were reported; 17 (34.0%) participants in the intervention arm and 15 (30.6%) in the control arm reported at least one adverse drug reaction, with no statistically significant overall between-group difference ( P = 0.82). Conclusion In adults with clinically diagnosed dementia and cognitive impairment of unconfirmed etiology, adjunctive pioglitazone did not produce a statistically significant improvement in cognitive performance over the 12-month study period. It also did not produce detectable between-group changes in the electrophysiological or exploratory plasma amyloid measures. Because AD pathology was not established with validated central or appropriately validated blood-based biomarkers, the findings should not be interpreted as evidence for or against a disease-modifying effect of pioglitazone in AD specifically. Clinical trial number CTRI2024/09/074281. Registered on 24/09/2024

Aging Clinical and Experimental Research
SRM Institute of Science and Technology (IN), SRM Medical College Hospital and Research Centre (IN)
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon